Metastatic Non-Clear Cell Renal Cell Carcinoma: An Evidence Based Review of Current Treatment Strategies

Much progress has been made in the treatment of metastatic renal cell carcinoma (RCC) over the last decade, with the development of agents that block the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway. The incorporation of these agents into trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Sankin, Alexander, Hakimi, A. Ari, Hsieh, James J., Molina, Ana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389537/
https://www.ncbi.nlm.nih.gov/pubmed/25905038
http://dx.doi.org/10.3389/fonc.2015.00067

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389537/
https://www.ncbi.nlm.nih.gov/pubmed/25905038
http://dx.doi.org/10.3389/fonc.2015.00067

Ejemplares similares